DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape.
The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The indication applies to use of the agent in adults ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Please provide your email address to receive an email when new articles are posted on . Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or ...
Eli Lilly and Co., through its Loxo@Lilly oncology unit, secured its second accelerated approval for non-covalent Bruton’s tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib), this time to treat ...
In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% ...
Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...
Venetoclax and ibrutinib are therapeutic agents for CLL. Continued approval required further verification and description of clinical benefit in confirmatory trials. Gilead Sciences has voluntarily ...
Fay said "the hardest chapter" of his life inspired him to create a nonprofit that initiates and inspires kind acts.
Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...
--Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Jaypirca ® for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback